Summary
57.69 0.69(1.21%)09/27/2024
Sanofi (SNY)
Sanofi (SNY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.14 | -0.12 | 2.46 | 20.04 | 16.38 | 8.91 | 39.50 | 296.36 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 57.69 | |
| Open | 57.16 | |
| High | 57.91 | |
| Low | 57.09 | |
| Volume | 1,899,545 | |
| Change | 0.65 | |
| Change % | 1.14 | |
| Avg Volume (20 Days) | 1,501,329 | |
| Volume/Avg Volume (20 Days) Ratio | 1.27 | |
| 52 Week Range | 42.63 - 58.97 | |
| Price vs 52 Week High | -2.17% | |
| Price vs 52 Week Low | 35.33% | |
| Range | 0.93 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 142,892 | |
| EBIDTA | 12,199,499,776 | |
| PE Ratio | 25.4021 | |
| PEG Ratio | 0.8375 | |
| WallStreet Target Price | 58.92 | |
| Book Value | 59.1680 | |
| Earnings Per Share | 1.9400 | |
| EPS Estimate Current Quarter | 0.9400 | |
| EPS Estimate Next Quarter | 0.9300 | |
| EPS Estimate Current Year | 4.1600 | |
| EPS Estimate Next Year | 4.9000 | |
| Diluted EPS (TTM) | 1.9400 | |
| Revenues | ||
| Profit Marging | 0.0980 | |
| Operating Marging (TTM) | 0.1828 | |
| Return on asset (TTM) | 0.0454 | |
| Return on equity (TTM) | 0.0727 | |
| Revenue TTM | 46,287,998,976 | |
| Revenue per share TTM | 18.4920 | |
| Quarterly Revenue Growth (YOY) | 0.0230 | |
| Quarterly Earnings Growth (YOY) | -0.4320 | |
| Gross Profit (TTM) | 31,697,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | 0.0413 | |
| Valuations | ||
| Trailing PE | 25.4021 | |
| Forward PE | 11.1359 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.4441 | |
| Revenue Enterprise Value | 2.7108 | |
| EBITDA Enterprise Value | 9.9891 | |
| Shares | ||
| Shares Outstanding | 2,499,209,984 | |
| Shares Float | 1,097,781,831 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 10.22 | |
09/27 17:18 EST - investopedia.com
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).
09/27 11:17 EST - benzinga.com
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”
09/27 09:39 EST - reuters.com
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday.
09/27 09:35 EST - globenewswire.com
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the US Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the US Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
09/27 07:00 EST - globenewswire.com
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan Dupixent is now approved in four indications across respiratory and dermatological diseases in China Paris and Tarrytown, New York, Sept. 27, 2024. The National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan Dupixent is now approved in four indications across respiratory and dermatological diseases in China Paris and Tarrytown, New York, Sept. 27, 2024. The National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
09/26 10:46 EST - zacks.com
Are Investors Undervaluing Sanofi (SNY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Sanofi (SNY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
09/26 10:41 EST - zacks.com
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
09/26 01:30 EST - globenewswire.com
Press Release: Availability of the Q3 2024 Aide mémoire
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2024 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
Press Release: Availability of the Q3 2024 Aide mémoire
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2024 results (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
09/24 14:18 EST - reuters.com
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday.
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday.
09/23 14:45 EST - zacks.com
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
09/23 11:13 EST - benzinga.com
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
09/23 11:01 EST - zacks.com
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
09/20 18:36 EST - globenewswire.com
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
09/20 15:40 EST - reuters.com
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday.
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday.
09/20 14:12 EST - seekingalpha.com
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
Sanofi (NASDAQ:SNY ) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toronto, Canada Robert Fox - MD, Mellen Center for MS, Cleveland Clinic, Cleveland, USA Houman Ashrafian - EVP, Head of Research and Development Erik Wallstroem - Global Senior VP, Head, Neurology Development Conference Call Participants Peter Verdult - Citi Colin Wyatt - Jefferies Luisa Hector - Berenberg Emily Field - Barclays Simon Baker - Atlantic Redburn Richard Vosser - JPMorgan Emmanuel Papadakis - Deutsche Bank Graham Parry - Bank of America Seamus Fernandez - Guggenheim Peter Verdult - Jefferies Eric Berrigaud - Stifel Nicolaus Thomas Kudsk Good afternoon from Copenhagen, and welcome to the Sanofi Investor Science Call from the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS 2024. I'm Thomas Kudsk from the Investor Relations team at Sanofi and we are here today for an update on Tolebrutinib, Sanofi's new medicine, intending to benefit patients with certain forms of multiple sclerosis.
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
Sanofi (NASDAQ:SNY ) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toronto, Canada Robert Fox - MD, Mellen Center for MS, Cleveland Clinic, Cleveland, USA Houman Ashrafian - EVP, Head of Research and Development Erik Wallstroem - Global Senior VP, Head, Neurology Development Conference Call Participants Peter Verdult - Citi Colin Wyatt - Jefferies Luisa Hector - Berenberg Emily Field - Barclays Simon Baker - Atlantic Redburn Richard Vosser - JPMorgan Emmanuel Papadakis - Deutsche Bank Graham Parry - Bank of America Seamus Fernandez - Guggenheim Peter Verdult - Jefferies Eric Berrigaud - Stifel Nicolaus Thomas Kudsk Good afternoon from Copenhagen, and welcome to the Sanofi Investor Science Call from the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS 2024. I'm Thomas Kudsk from the Investor Relations team at Sanofi and we are here today for an update on Tolebrutinib, Sanofi's new medicine, intending to benefit patients with certain forms of multiple sclerosis.
09/20 07:45 EST - globenewswire.com
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris and Tarrytown, NY, September 20, 2024. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union (EU) for eosinophilic esophagitis (EoE) in children down to 1 year of age.
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris and Tarrytown, NY, September 20, 2024. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union (EU) for eosinophilic esophagitis (EoE) in children down to 1 year of age.
09/20 05:54 EST - reuters.com
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
09/20 05:30 EST - globenewswire.com
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
09/19 16:01 EST - zacks.com
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
09/17 14:30 EST - https://www.prnewswire.com
Squalene Market to Grow by USD 62.9 Million from 2024-2028, Driven by Rising Adoption of UVA/UVB Filters in Sunscreens, Report Powered by AI - Technavio
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.79% during the forecast period. Increasing acceptance of uva/b filters in sunscreens and sun protection cosmetics is driving market growth, with a trend towards squalene derived from renewable resources. However, stringent safety regulations on uv sun care products poses a challenge. Key market players include Amyris Inc., ARISTA INDUSTRIES, BOCSCI Inc., Cibus, Croda International Plc, Evonik Industries AG, Gracefruit Ltd., KISHIMOTO SPECIAL LIVER OIL CO. LTD., KURARAY Co. Ltd., LBB Specialties LLC, MacroCare Tech Ltd., Majestic Mountain Sage Inc., Maruha Nichiro Corp., Maypro Group, Micro Capsule Technologies, New Zealand Green Health Ltd., Parchem Fine and Specialty Chemicals Inc., Seadragon, Sophim, and VESTAN. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver Squalene, a natural hydrocarbon, is increasingly derived from renewable sources such as vegetables and olives. Olive oil is a significant source due to its high squalene content. Renewable squalene production is expanding in countries with abundant olive cultivation, including Greece, Portugal, Italy, France, Spain, the US, Australia, Turkey, and Austria. Sugarcane is another source, yielding squalene of higher quality and purity. Squalene is used in skin treatments and personal care products derived from olive oil and sugarcane. Additionally, squalene is sourced from tobacco and a new yeast-like fungus, Pseudozyma, for commercial production. Genetic modification and metabolic changes have enhanced squalene production, leading to the development of industrial-scale, squalene-hyperproducing strains. This trend towards renewable squalene sources is anticipated to continue, positively impacting the global squalene market's growth during the forecast period. Squalene is a popular ingredient in the personal care industry, used in creams, serums, oils, and masks for its excellent moisturizing properties. Traditionally sourced from shark liver oil, concerns over animal welfare and sustainability have led to the exploration of renewable sources. Sugarcane and olive-derived squalene are now common alternatives. Vegetable-sourced squalene, also known as squalane, is gaining popularity due to its lower toxicity and compatibility with various formulations. Emollients in lotions, hair conditioners, bath oils, lipsticks, foundations, and even vaccines benefit from squalene's ability to reduce the oxidation of other ingredients and enhance their efficacy. Squalene's role in the cosmetics sector extends to cleansing ingredients in various personal care products. In the nutritional supplement market, fish oil and shark liver oil remain significant sources of squalene, contributing to immune response and vaccine development. Renowned companies like GlaxoSmithKline, Sanofi S, and CureVac N are investing in squalene research for its potential as an adjuvant in flu vaccinations, enhancing immunogenicity and antigen dosage sparing. However, the use of squalene in vaccines has raised concerns regarding its potential toxicity and heterologous antibody responses. The oncology segment is also exploring squalene for its potential role in cancer treatment. Overall, the versatility of squalene makes it an essential raw material in various industries, from personal care to pharmaceuticals. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This squalene market report extensively covers market segmentation by 1.1 Cosmetic and personal care products- The global squalene market is primarily driven by the cosmetics and personal care sector, with squalene and squalane being key ingredients due to their skin benefits. Squalene, a natural organic substance, is sourced from olives, wheat germ oil, and rice bran. It acts as a precursor to cholesterol and aids in skin moisturization and protection. Squalane, derived from squalene through hydrogenation, is a stable form for skincare products. Both offer moisturizing, anti-aging, anti-inflammatory, and healing properties. In cosmetics, they're used in hair care, makeup, skincare, and sunscreen products. They improve skin texture, reduce fine lines, protect from environmental stressors, and strengthen the skin's barrier function. Squalane is lightweight, noncomedogenic, and suitable for all skin types. Its humectant property retains skin moisture and has antibacterial properties. The expanding cosmetics industry, growing consumer spending, and increasing demand for premium products fuel the market's growth during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Squalene is a natural hydrocarbon found in various sources, including shark liver oil and certain plant-based sources like olives, rice bran, amaranth oil, and sugarcane. In the personal care and cosmetics sector, squalene is widely used as an emollient due to its excellent moisturizing properties. It is commonly found in creams, serums, and oils, and is known for its ability to penetrate deep into the skin, making it an effective anti-aging ingredient. Animal-sourced squalene, primarily from shark liver oil, has faced controversy due to concerns over shark populations and toxicity. However, the cosmetics industry has shifted towards vegetable-sourced squalene as a more sustainable and ethical alternative. Free radicals are unstable molecules that can damage skin cells and contribute to the aging process. Squalene is a potent antioxidant that helps protect the skin from damage caused by free radicals. The MMPA (Marine Mammal Protection Act) regulates the harvesting of shark liver oil, ensuring that it is sustainably sourced. Nutraceutical firms also use squalene for its health benefits, such as reducing inflammation and improving skin elasticity. Terpene oils, like tea tree oil and sandalwood oil, can be rich sources of squalene. Tobacco crops are also being explored as a potential source of squalene, but its extraction is still under research. Overall, squalene is a versatile ingredient with numerous applications in personal care and cosmetics, as well as in nutraceuticals, and its sourcing is becoming increasingly sustainable and ethical. Market Research Overview Squalene is a natural hydrocarbon found in various organisms, including sharks, olives, and sugarcane. In the personal care industry, squalene is widely used as a raw material for creating emollients in creams, serums, oils, masks, lotions, hair conditioners, bath oils, lipsticks, foundations, and more. Squalene's ability to mimic the skin's natural oils makes it an excellent moisturizing agent and cleansing ingredient. Animal-sourced squalene, primarily obtained from shark liver oil, has raised concerns regarding the impact on shark populations. Renewable sources, such as sugarcane and vegetable-sourced squalene, have gained popularity as alternatives. Squalene's antioxidant properties help protect the skin from free radicals and the aging process. Beyond personal care, squalene is also used in vaccines as an adjuvant to enhance immunogenicity and reduce antigen dosage sparing. Companies like GlaxoSmithKline, Sanofi Pasteur, and CureVac are some key players in this segment. Squalene's use extends to the oncology segment for its potential anti-aging properties and as a component in terpene oils, such as amaranth oil and rice bran oil. Squalene's applications go beyond personal care and cosmetics. It is also used in nutraceuticals and nutritional supplements, such as fish oil and plant-based squalene. In the pharmaceutical industry, squalene is used as a raw material for producing synthetic squalene for various applications, including flu vaccinations. However, it is important to note that while squalene is generally considered safe, there have been reports of allergic reactions and toxicity in some individuals. Therefore, it is essential to use squalene-containing products responsibly and consult a healthcare professional if any adverse reactions occur. Table of Contents: 1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation 7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]Website: www.technavio.com/
Squalene Market to Grow by USD 62.9 Million from 2024-2028, Driven by Rising Adoption of UVA/UVB Filters in Sunscreens, Report Powered by AI - Technavio
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.79% during the forecast period. Increasing acceptance of uva/b filters in sunscreens and sun protection cosmetics is driving market growth, with a trend towards squalene derived from renewable resources. However, stringent safety regulations on uv sun care products poses a challenge. Key market players include Amyris Inc., ARISTA INDUSTRIES, BOCSCI Inc., Cibus, Croda International Plc, Evonik Industries AG, Gracefruit Ltd., KISHIMOTO SPECIAL LIVER OIL CO. LTD., KURARAY Co. Ltd., LBB Specialties LLC, MacroCare Tech Ltd., Majestic Mountain Sage Inc., Maruha Nichiro Corp., Maypro Group, Micro Capsule Technologies, New Zealand Green Health Ltd., Parchem Fine and Specialty Chemicals Inc., Seadragon, Sophim, and VESTAN. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver Squalene, a natural hydrocarbon, is increasingly derived from renewable sources such as vegetables and olives. Olive oil is a significant source due to its high squalene content. Renewable squalene production is expanding in countries with abundant olive cultivation, including Greece, Portugal, Italy, France, Spain, the US, Australia, Turkey, and Austria. Sugarcane is another source, yielding squalene of higher quality and purity. Squalene is used in skin treatments and personal care products derived from olive oil and sugarcane. Additionally, squalene is sourced from tobacco and a new yeast-like fungus, Pseudozyma, for commercial production. Genetic modification and metabolic changes have enhanced squalene production, leading to the development of industrial-scale, squalene-hyperproducing strains. This trend towards renewable squalene sources is anticipated to continue, positively impacting the global squalene market's growth during the forecast period. Squalene is a popular ingredient in the personal care industry, used in creams, serums, oils, and masks for its excellent moisturizing properties. Traditionally sourced from shark liver oil, concerns over animal welfare and sustainability have led to the exploration of renewable sources. Sugarcane and olive-derived squalene are now common alternatives. Vegetable-sourced squalene, also known as squalane, is gaining popularity due to its lower toxicity and compatibility with various formulations. Emollients in lotions, hair conditioners, bath oils, lipsticks, foundations, and even vaccines benefit from squalene's ability to reduce the oxidation of other ingredients and enhance their efficacy. Squalene's role in the cosmetics sector extends to cleansing ingredients in various personal care products. In the nutritional supplement market, fish oil and shark liver oil remain significant sources of squalene, contributing to immune response and vaccine development. Renowned companies like GlaxoSmithKline, Sanofi S, and CureVac N are investing in squalene research for its potential as an adjuvant in flu vaccinations, enhancing immunogenicity and antigen dosage sparing. However, the use of squalene in vaccines has raised concerns regarding its potential toxicity and heterologous antibody responses. The oncology segment is also exploring squalene for its potential role in cancer treatment. Overall, the versatility of squalene makes it an essential raw material in various industries, from personal care to pharmaceuticals. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This squalene market report extensively covers market segmentation by 1.1 Cosmetic and personal care products- The global squalene market is primarily driven by the cosmetics and personal care sector, with squalene and squalane being key ingredients due to their skin benefits. Squalene, a natural organic substance, is sourced from olives, wheat germ oil, and rice bran. It acts as a precursor to cholesterol and aids in skin moisturization and protection. Squalane, derived from squalene through hydrogenation, is a stable form for skincare products. Both offer moisturizing, anti-aging, anti-inflammatory, and healing properties. In cosmetics, they're used in hair care, makeup, skincare, and sunscreen products. They improve skin texture, reduce fine lines, protect from environmental stressors, and strengthen the skin's barrier function. Squalane is lightweight, noncomedogenic, and suitable for all skin types. Its humectant property retains skin moisture and has antibacterial properties. The expanding cosmetics industry, growing consumer spending, and increasing demand for premium products fuel the market's growth during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Squalene is a natural hydrocarbon found in various sources, including shark liver oil and certain plant-based sources like olives, rice bran, amaranth oil, and sugarcane. In the personal care and cosmetics sector, squalene is widely used as an emollient due to its excellent moisturizing properties. It is commonly found in creams, serums, and oils, and is known for its ability to penetrate deep into the skin, making it an effective anti-aging ingredient. Animal-sourced squalene, primarily from shark liver oil, has faced controversy due to concerns over shark populations and toxicity. However, the cosmetics industry has shifted towards vegetable-sourced squalene as a more sustainable and ethical alternative. Free radicals are unstable molecules that can damage skin cells and contribute to the aging process. Squalene is a potent antioxidant that helps protect the skin from damage caused by free radicals. The MMPA (Marine Mammal Protection Act) regulates the harvesting of shark liver oil, ensuring that it is sustainably sourced. Nutraceutical firms also use squalene for its health benefits, such as reducing inflammation and improving skin elasticity. Terpene oils, like tea tree oil and sandalwood oil, can be rich sources of squalene. Tobacco crops are also being explored as a potential source of squalene, but its extraction is still under research. Overall, squalene is a versatile ingredient with numerous applications in personal care and cosmetics, as well as in nutraceuticals, and its sourcing is becoming increasingly sustainable and ethical. Market Research Overview Squalene is a natural hydrocarbon found in various organisms, including sharks, olives, and sugarcane. In the personal care industry, squalene is widely used as a raw material for creating emollients in creams, serums, oils, masks, lotions, hair conditioners, bath oils, lipsticks, foundations, and more. Squalene's ability to mimic the skin's natural oils makes it an excellent moisturizing agent and cleansing ingredient. Animal-sourced squalene, primarily obtained from shark liver oil, has raised concerns regarding the impact on shark populations. Renewable sources, such as sugarcane and vegetable-sourced squalene, have gained popularity as alternatives. Squalene's antioxidant properties help protect the skin from free radicals and the aging process. Beyond personal care, squalene is also used in vaccines as an adjuvant to enhance immunogenicity and reduce antigen dosage sparing. Companies like GlaxoSmithKline, Sanofi Pasteur, and CureVac are some key players in this segment. Squalene's use extends to the oncology segment for its potential anti-aging properties and as a component in terpene oils, such as amaranth oil and rice bran oil. Squalene's applications go beyond personal care and cosmetics. It is also used in nutraceuticals and nutritional supplements, such as fish oil and plant-based squalene. In the pharmaceutical industry, squalene is used as a raw material for producing synthetic squalene for various applications, including flu vaccinations. However, it is important to note that while squalene is generally considered safe, there have been reports of allergic reactions and toxicity in some individuals. Therefore, it is essential to use squalene-containing products responsibly and consult a healthcare professional if any adverse reactions occur. Table of Contents: 1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation 7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]Website: www.technavio.com/